ArticleHead and neck pathology2021
NUT Carcinoma in a Patient with Unusually Long Survival and False Negative FISH Results.
Article in Head and neck pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Anti-angiogenic therapy as a beacon of hope in the battle against pulmonary NUT midline carcinoma.Frontiers of medicine · 2025Pooled it
- Hospital-Compounded Birabresib Capsules for NUT Carcinoma: A Quality- and Risk-Based CMC Strategy.Pharmaceutical research · 2026Article
- Intraductal Salivary Gland Neoplasms of the Oral Cavity: A Retrospective Case Series with Emphasis on Newly Described Entities.Head and neck pathology · 2026Article
- International guidelines on the diagnosis and treatment of NUT carcinoma.Innovation (Cambridge (Mass.)) · 2026Review
- Pediatric NUT carcinoma: a patient series and literature review.BMC pediatrics · 2025Review
- NUT Carcinoma of the Head and Neck: Clinicopathologic and Molecular Analysis of 18 Cases.Head and neck pathology · 2025Article
- Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck.Nature reviews. Clinical oncology · 2025Review
- NUT carcinoma of the head and neck: A case report and literature review.Precision radiation oncology · 2024Review
- The histological spectrum and immunoprofile of head and neck NUT carcinoma: A multicentre series of 30 cases.Histopathology · 2024Article
- A Rare Case of P63-Negative Sinonasal Nut Midline Carcinoma in the Elderly.European journal of case reports in internal medicine · 2024Article
- Sinonasal NUT carcinoma: A retrospective case series from a single institution.Frontiers in surgery · 2023Article
- NUTM1-fusion positive malignant neoplasms of the genitourinary tract: A report of six cases highlighting involvement of unusual anatomic locations and histologic heterogeneity.Genes, chromosomes & cancer · 2022Article
- NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics.Frontiers in oncology · 2022Review
- Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma.Frontiers in oncology · 2021Review
- Diagnosis of NUT Carcinoma Despite False-Negative Next-Generation Sequencing Results: A Case Report and Literature Review.OncoTargets and therapy · 2021Article
- Long-Term Survival following Trimodal Therapy Including Hyperfractionated Radiotherapy in Parotid NUT Carcinoma: A 29-Month Follow-Up Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear protein in testis (NUT) carcinoma is a rare and highly aggressive epithelial malignancy defined by rearrangement of the NUTM1 gene on chromosome 15q14. Histologically, NUT carcinoma is an undifferentiated carcinoma formed by sheets and nests of primitive and monotonous "round blue cells" with foci of abrupt keratinization in a subset. NUT carcinoma runs a fulminant clinical course and is almost always quickly lethal, with a median overall survival of only 6.7 months. There is no consensus regarding treatment for this disease, and most patients respond poorly to conventional chemotherapy and radiation. We report a case of NUT carcinoma in an African-American man who initially presented in 2009 with a tracheal mass at age 28. Although fluorescence in situ hybridization (FISH) assays for NUTM1 and BRD4 rearrangements were negative, he was diagnosed based on diffusely positive NUT immunostaining and BRD4-NUTM1 on RNA sequencing. Since his initial presentation, he has undergone multiple surgical procedures and radiation therapy. His tumor has recurred twice, but he has survived for 129 months and is currently alive without disease. Long-term survival of patients with NUT carcinoma is incredibly unusual, especially in patients with tumors that exhibit a BRD4 rearrangement. False negative FISH is a pitfall in diagnosing NUT carcinoma; NUT immunostaining and RNA sequencing are more sensitive diagnostic methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.